生存期-话题@MedSci

#生存期#

350篇内容 | 2799人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378268, encodeId=cd3213e8268b6, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=卡瑞利珠单抗创造肺癌最长总生存期, objectType=article, longId=204726, objectId=e8bb204e26f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8bb204e26f4, replyNumber=0, likeNumber=88, createdTime=2020-12-22, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8bb204e26f4, moduleTitle=卡瑞利珠单抗创造肺癌最长总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8bb204e26f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378267, encodeId=406213e8267b0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, objectType=article, longId=204591, objectId=0d4f2045916e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4f2045916e, replyNumber=0, likeNumber=79, createdTime=2020-12-18, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4f2045916e, moduleTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4f2045916e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378266, encodeId=898013e8266f2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=J Clin Oncol：他莫昔芬联合卵巢抑制功能可显著延长绝经前乳腺癌患者的无病生存期, objectType=article, longId=204393, objectId=ba5320439337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba5320439337, replyNumber=0, likeNumber=78, createdTime=2020-12-12, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba5320439337, moduleTitle=J Clin Oncol：他莫昔芬联合卵巢抑制功能可显著延长绝经前乳腺癌患者的无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba5320439337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378265, encodeId=26cb13e826524, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Ann Surg：肝移植可为不可切除性肝转移的结直肠癌患者提供较长的总生存期, objectType=article, longId=204219, objectId=312820421978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=312820421978, replyNumber=0, likeNumber=105, createdTime=2020-12-08, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=312820421978, moduleTitle=Ann Surg：肝移植可为不可切除性肝转移的结直肠癌患者提供较长的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=312820421978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378264, encodeId=069313e82641e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Gastroen Hepatol：术后腹腔灌洗不能提高胃癌根治术患者生存期, objectType=article, longId=204006, objectId=75ed20400612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75ed20400612, replyNumber=0, likeNumber=83, createdTime=2020-12-03, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75ed20400612, moduleTitle=Lancet Gastroen Hepatol：术后腹腔灌洗不能提高胃癌根治术患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75ed20400612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378263, encodeId=062313e8263ec, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Br J Cancer：RAS突变对于早发性和晚发性结直肠癌肝转移切除患者总体生存期的影响, objectType=article, longId=203813, objectId=1a49203813ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a49203813ee, replyNumber=0, likeNumber=81, createdTime=2020-11-28, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a49203813ee, moduleTitle=Br J Cancer：RAS突变对于早发性和晚发性结直肠癌肝转移切除患者总体生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a49203813ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378262, encodeId=033113e8262f5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, objectType=article, longId=203482, objectId=6ec6203482bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ec6203482bb, replyNumber=0, likeNumber=62, createdTime=2020-11-18, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ec6203482bb, moduleTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ec6203482bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378261, encodeId=d09f13e82610a, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月, objectType=article, longId=202159, objectId=6ecb20215929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ecb20215929, replyNumber=0, likeNumber=70, createdTime=2020-10-17, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ecb20215929, moduleTitle=真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ecb20215929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378260, encodeId=7df513e8260e8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益, objectType=article, longId=201226, objectId=f204201226fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f204201226fd, replyNumber=0, likeNumber=60, createdTime=2020-09-27, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f204201226fd, moduleTitle=ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f204201226fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378259, encodeId=48a213e8259c3, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=欧狄沃辅助治疗食管癌及胃食管连接部癌术后患者可显著提高无病生存期, objectType=article, longId=201111, objectId=77a120111131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a120111131, replyNumber=0, likeNumber=73, createdTime=2020-09-25, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a120111131, moduleTitle=欧狄沃辅助治疗食管癌及胃食管连接部癌术后患者可显著提高无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77a120111131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378258, encodeId=004c13e825801, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=45, createdTime=2020-09-24, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378257, encodeId=823a13e825792, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Oncol：多喝咖啡还能减少结直肠癌死亡，延长生存期, objectType=article, longId=200966, objectId=e38d20096645, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e38d20096645, replyNumber=0, likeNumber=85, createdTime=2020-09-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e38d20096645, moduleTitle=JAMA Oncol：多喝咖啡还能减少结直肠癌死亡，延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e38d20096645)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378256, encodeId=34c413e82569d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期, objectType=article, longId=200935, objectId=015b2009357f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015b2009357f, replyNumber=0, likeNumber=72, createdTime=2020-09-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015b2009357f, moduleTitle=2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015b2009357f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378255, encodeId=466d13e82558e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, objectType=article, longId=199750, objectId=6fb7199e501c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb7199e501c, replyNumber=0, likeNumber=73, createdTime=2020-08-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb7199e501c, moduleTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb7199e501c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378254, encodeId=a09c13e825463, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Oncol ：ER+/N+合并多种并发症的老年乳腺癌患者中，化疗与生存期的关系, objectType=article, longId=199650, objectId=ad2819965083, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad2819965083, replyNumber=0, likeNumber=139, createdTime=2020-08-20, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad2819965083, moduleTitle=JAMA Oncol ：ER+/N+合并多种并发症的老年乳腺癌患者中，化疗与生存期的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad2819965083)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378253, encodeId=ed4713e825396, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Dig Liver Dis: 自身免疫性肝炎患者血清免疫球蛋白G水平正常化与无移植生存期改善有关, objectType=article, longId=199365, objectId=f82f199365ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f82f199365ec, replyNumber=0, likeNumber=101, createdTime=2020-08-15, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f82f199365ec, moduleTitle=Dig Liver Dis: 自身免疫性肝炎患者血清免疫球蛋白G水平正常化与无移植生存期改善有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f82f199365ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378252, encodeId=5cb713e825250, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, objectType=article, longId=199310, objectId=a5e8199310d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e8199310d0, replyNumber=0, likeNumber=53, createdTime=2020-08-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e8199310d0, moduleTitle=食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e8199310d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378251, encodeId=255013e82519c, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=52, createdTime=2020-08-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378250, encodeId=adc913e8250cb, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, objectType=article, longId=198887, objectId=e4c319888efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c319888efe, replyNumber=0, likeNumber=70, createdTime=2020-08-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c319888efe, moduleTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c319888efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378249, encodeId=c9db13e8249da, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, objectType=article, longId=198728, objectId=a9fa198e28d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9fa198e28d9, replyNumber=0, likeNumber=73, createdTime=2020-08-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9fa198e28d9, moduleTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9fa198e28d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

卡瑞利珠单抗创造肺癌最长总生存期

2020-12-22

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床

2020-12-18

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

J Clin Oncol：他莫昔芬联合卵巢抑制功能可显著延长绝经前乳腺癌患者的无病生存期

2020-12-12

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

Ann Surg：肝移植可为不可切除性肝转移的结直肠癌患者提供较长的总生存期

2020-12-08

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

Lancet Gastroen Hepatol：术后腹腔灌洗不能提高胃癌根治术患者生存期

2020-12-03

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

Br J Cancer：RAS突变对于早发性和晚发性结直肠癌肝转移切除患者总体生存期的影响

2020-11-28

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期

2020-11-18

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

真实世界研究表明，在晚期前列腺癌治疗方案中增加细胞疗法PROVENGE（sipuleucel-T）可使中位生存期延长14.5个月

2020-10-17

一叶知秋 (审核中...)

前往app查看评论内容

#生存期#

ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益

2020-09-27

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

欧狄沃辅助治疗食管癌及胃食管连接部癌术后患者可显著提高无病生存期

2020-09-25

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2020-09-24

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA Oncol：多喝咖啡还能减少结直肠癌死亡，延长生存期

2020-09-22

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期

2020-09-21

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期

2020-08-22

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA Oncol ：ER+/N+合并多种并发症的老年乳腺癌患者中，化疗与生存期的关系

2020-08-20

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Dig Liver Dis: 自身免疫性肝炎患者血清免疫球蛋白G水平正常化与无移植生存期改善有关

2020-08-15

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

食管癌及胃食管连接部癌术后欧狄沃（纳武利尤单抗）辅助治疗III期临床研究CheckMate -577达到主要终点无病生存期

2020-08-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2020-08-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期

2020-08-08

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期

2020-08-06

科室
- - 订阅+
  - 更多科室
工具
服务